Besides that, multiple studies have implied that inhibiting HIF1α could be a potential approach for ESCC treatment [13, 14], indicating that MALAT1 may upregulate the expression of HIF1α by targeting miR-199a and thereby mediate radioresistance. Here, HIF1A is linked to esophageal squamous cell carcinoma.